May 14, 2020 / 9:51 PM / 11 days ago

BRIEF-Lumos Pharma Says Has Had To Re-Evaluate Timing Of Phase 2B Clinical Trial For Product Candidate LUM-201

May 14 (Reuters) - Lumos Pharma Inc:

* LUMOS PHARMA INC - HAS HAD TO RE-EVALUATE TIMING OF ITS PHASE 2B CLINICAL TRIAL FOR ITS PRODUCT CANDIDATE LUM-201

* LUMOS PHARMA INC - NOW EXPECTS TO INITIATE ITS PHASE 2B TRIAL IN PEDIATRIC GROWTH HORMONE DEFICIENCY PRIOR TO END OF 2020 Source text: (bit.ly/2X11qh8) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below